Impact of genomic instability in risk assessment and chemoprevention of oral premalignancies

International Journal of Cancer

Volumn 101, Issue 3, 2002, Pages 205-209

  Reith, Albrecht ^a   Sudbø, Jon ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cancer risk; Chemoprevention; Cyclooxygenase 2; DNA ploidy; Early diagnosis; Gross genomic aberration; Head and neck cancer; Premalignant oral lesion; Prognosis

Indexed keywords

CYCLOOXYGENASE 2;

CANCER RISK; CHEMOPROPHYLAXIS; EARLY DIAGNOSIS; HEAD AND NECK CANCER; HIGH RISK POPULATION; HUMAN; LEUKOPLAKIA; MICROSATELLITE INSTABILITY; MOUSE; NONHUMAN; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOPREVENTION; CHROMOSOME ABERRATIONS; CLINICAL TRIALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOUTH NEOPLASMS; PLOIDIES; PROGNOSIS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 0037144362     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10569     Document Type: Short Survey

References (73)

1. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population
2. Estimating the world cancer burden: Globocan 2000
3. Estimates of the worldwide mortality from 25 cancers in 1990
4. Global cancer statistics
5. Squamous cell carcinoma of the oral cavity, pharynx, and larynx in young adults
6. Rising mortality from cancer of the tongue in young Scottish males
7. Rising trends of oral cancer mortality among males worldwide: The return of an old public health problem
8. Trends of oral cancer mortality among females worldwide
9. Head and neck cancer
10. Head and neck cancer
11. Gross genomic aberrations in precancers: Clinical implications of a long-term follow-up study in oral erythroplakias
12. DNA content as a prognostic marker in patients with oral leukoplakias
13. Predicting cancer development in oral leukoplakia: Ten years of translational research
14. Oral leukoplakia and erythroplakia: A review and update
15. Erythroplakia: The dangerous red mucosa
16. Epidemiologic and demographic update in oral cancer: California and national data - 1973 to 1985
17. Leukoplakia revisited. A clinicopathologic study of 3256 oral leukoplakias
18. Malignancy grading in oral squamous cell carcinoma. I. Squamous cell carcinoma of the tongue and floor of mouth: Histologic grading in the clinical evaluation
19. Observer variability in the histologic assessment of oral premalignant lesions
20. Comparison of histological grading and large scale genomic status (DNA ploidy) as prognostic tools in oral dysplasia
21. Abnormal DNA content predicts the occurence of carcinomas in non-dysplastic oral white patches
22. Erythroplakia of the oral cavity
23. Lack of molecular markers to predict malignant potential of oral precancer
24. Oral precancer: Preventive and medical approaches to management
25. Oral leukoplakias: To treat or not?
26. Malignant transformation of leukoplakia
27. Surrogate anatomic/functional sites for evaluating cancer risk: An extension of the field effect
28. Are we ready to use surrogate end points and surrogate tissues to evaluate response to chemopreventive and therapeutic intervention?
29. Multiple primary tumours in patients with oral squamous cell carcinoma
30. Synchronous and metachronous head and neck carcinomas
31. Multiple primary cancer in patients with cancer of the head and neck: Second cancer of the head and neck, oesophagus and lung
32. Field cancerization in oral stratified squamous epithelium: Clinical implications of multicentric origin
33. Accumulative increase of loss of heterozygosity from leukoplakia to foci of early cancerization in leukoplakia of the oral cavity
34. Suprabasal p53 immunoexpression is strongly associated with high grade dysplasia and risk for malignant transformation in potentially malignant oral lesions from Northern Ireland
35. Prevalence of p53, bcl-2, and Ki-67 immunoreactivity and of apoptosis in normal oral epithelium and in premalignant and malignant lesions of the oral cavity
36. Diagnostic implications of p53 protein reactivity in nasal mucosa of nickel workers
37. p53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas
38. Why is p53 protein stabilized in neoplasia? Some answers but many more questions?
39. The pattern of expression of the 5T4 oncofoetal antigen on normal, dysplastic and malignant oral mucosa
40. Telomerase activity in oral and maxillofacial tumors
41. Telomere and telomerase in oncology
42. Altered expression of alpha 6 integrin subunit in oral squamous cell carcinoma and oral potentially malignant lesions
43. Cell cycle control and cancer
44. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control
45. Genetic aberrations in oral or head and neck squamous cell carcinoma: 2. Chromosomal aberrations
46. Genetic aberrations in oral or head and neck squamous cell carcinoma: 3. Clinico-pathological applications
47. Aneuploidy and cancer
48. The spindle checkpoint: Two transitions, two pathways
49. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: A phenotype/genotype correlation
50. Characterization of MAD2B and other mitotic spindle checkpoint genes
51. Genetic instabilities in human cancers
52. Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations
53. Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas
54. MAD2 haploinsufficiency causes premature anaphase and chromosome instability in mammalian cells
55. Unknown primary head and neck squamous cell carcinoma: Molecular identification of the site of origin
56. Genome wide screening identified gains and losses as independent prognostic variables in patients with head and neck squamous cell carcinomas (HNSCC)
57. Long-term regional control after radiation therapy and neck dissection for base of tongue carcinoma
58. Is COX-2 inhibition a panacea for cancer prevention?
59. Cytologic and DNA-cytometric early diagnosis of oral cancer
60. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
61. Expression of cyclooxygenase-2 in human gastric carcinoma
62. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder
63. Cyclooxygenase-2 expression in human esophageal carcinoma
64. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
65. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
66. Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer
67. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice
68. Studies on biomarkers in cancer etiology and prevention: A summary and challenge of 20 years of interdisciplinary research
69. Etheno DNA-base adducts from endogenous reactive species
70. Ultrasensitive and specific detection methods for exocylic DNA adducts: Markers for lipid peroxidation and oxidative stress
71. Exocyclic DNA adducts as secondary markers for oxidative stress: Applications in human cancer etiology and risk assessment
72. Laryngeal mucosa of head and neck cancer patients shows increased DNA damage as detected by single cell microgel electrophoresis
73. Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer